103 related articles for article (PubMed ID: 17230496)
1. Expression of Gadd45a and p53 proteins in human pancreatic cancer: potential effects on clinical outcomes.
Dong M; Dong Q; Zhang H; Zhou J; Tian Y; Dong Y
J Surg Oncol; 2007 Mar; 95(4):332-6. PubMed ID: 17230496
[TBL] [Abstract][Full Text] [Related]
2. [Expressions of p53 and Gadd45a proteins in human pancreatic cancer and their clinicopathological significance].
Dong M; Zhou JP; Kong FM; Guo KJ; Tian YL; Dong YT
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Oct; 27(5):628-32. PubMed ID: 16274047
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer.
Yamasawa K; Nio Y; Dong M; Yamaguchi K; Itakura M
Clin Cancer Res; 2002 Aug; 8(8):2563-9. PubMed ID: 12171884
[TBL] [Abstract][Full Text] [Related]
4. Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions.
Hermanova M; Trna J; Nenutil R; Dite P; Kala Z
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):732-9. PubMed ID: 18617777
[TBL] [Abstract][Full Text] [Related]
5. Adenoviral-mediated gene transfer of Gadd45a results in suppression by inducing apoptosis and cell cycle arrest in pancreatic cancer cell.
Li Y; Qian H; Li X; Wang H; Yu J; Liu Y; Zhang X; Liang X; Fu M; Zhan Q; Lin C
J Gene Med; 2009 Jan; 11(1):3-13. PubMed ID: 19003803
[TBL] [Abstract][Full Text] [Related]
6. Expression of retinoblastoma and p53 pathway-related proteins in resectable invasive ductal carcinoma of the pancreas: potential cooperative effects on clinical outcome.
Hashimoto K; Nio Y; Koike M; Itakura M; Yano S; Higami T; Maruyama R
Anticancer Res; 2005; 25(2B):1361-8. PubMed ID: 15865092
[TBL] [Abstract][Full Text] [Related]
7. p53 expression affects the efficacy of adjuvant chemotherapy after resection of invasive ductal carcinoma of the pancreas.
Nio Y; Dong M; Uegaki K; Hirahara N; Minari Y; Sasaki S; Takamura M; Iguchi C; Tamura K
Anticancer Res; 1998; 18(5B):3773-9. PubMed ID: 9854494
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of expression of p21 and p53 proteins and proliferating cell nuclear antigen in pancreatic cancer.
Dang CX; Han Y; Qin ZY; Wang YJ
Hepatobiliary Pancreat Dis Int; 2002 May; 1(2):302-5. PubMed ID: 14612290
[TBL] [Abstract][Full Text] [Related]
9. High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients.
Vimalachandran D; Greenhalf W; Thompson C; Lüttges J; Prime W; Campbell F; Dodson A; Watson R; Crnogorac-Jurcevic T; Lemoine N; Neoptolemos J; Costello E
Cancer Res; 2005 Apr; 65(8):3218-25. PubMed ID: 15833853
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival.
Giaginis C; Katsamangou E; Tsourouflis G; Zizi-Serbetzoglou D; Kouraklis G; Theocharis S
Med Sci Monit; 2009 May; 15(5):BR148-56. PubMed ID: 19396032
[TBL] [Abstract][Full Text] [Related]
11. CD44 isoforms expression in intraductal and invasive pancreatic cancer and its correlation to p53 gene mutations.
Tomaszewska R; Nowak K; Stachura J
Pol J Pathol; 1999; 50(3):145-53. PubMed ID: 10624116
[TBL] [Abstract][Full Text] [Related]
12. p53 protein expression as prognostic factor in human pancreatic cancer.
Sato Y; Nio Y; Song MM; Sumi S; Hirahara N; Minari Y; Tamura K
Anticancer Res; 1997; 17(4A):2779-88. PubMed ID: 9252715
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas.
Zhang SY; Ruggeri B; Agarwal P; Sorling AF; Obara T; Ura H; Namiki M; Klein-Szanto AJ
Arch Pathol Lab Med; 1994 Feb; 118(2):150-4. PubMed ID: 8311654
[TBL] [Abstract][Full Text] [Related]
14. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Ioachim E
Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
[TBL] [Abstract][Full Text] [Related]
15. Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings.
Khan Z; Tiwari RP; Mulherkar R; Sah NK; Prasad GB; Shrivastava BR; Bisen PS
Head Neck; 2009 Aug; 31(8):1039-48. PubMed ID: 19340865
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of MUC1 in advanced pancreatic cancer.
Hinoda Y; Ikematsu Y; Horinochi M; Sato S; Yamamoto K; Nakano T; Fukui M; Suehiro Y; Hamanaka Y; Nishikawa Y; Kida H; Waki S; Oka M; Imai K; Yonezawa S
J Gastroenterol; 2003; 38(12):1162-6. PubMed ID: 14714254
[TBL] [Abstract][Full Text] [Related]
17. Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival.
Casneuf VF; Fonteyne P; Van Damme N; Demetter P; Pauwels P; de Hemptinne B; De Vos M; Van de Wiele C; Peeters M
Cancer Invest; 2008 Oct; 26(8):852-9. PubMed ID: 18853313
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine cells in pancreatic duct adenocarcinoma: an immunohistochemical study.
Linder S; Myrvold K; Falkmer UG; Qvigstad G; Waldum HL; Falkmer SE
J Exp Clin Cancer Res; 2006 Jun; 25(2):213-21. PubMed ID: 16918133
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of angiogenesis and its correlations with thymidine phosphorylase and p53 expression in ductal adenocarcinoma of the pancreas.
Jinfeng M; Kimura W; Sakurai F; Moriya T; Mizutani M; Hirai I
Hepatogastroenterology; 2007 Sep; 54(78):1635-40. PubMed ID: 18019682
[TBL] [Abstract][Full Text] [Related]
20. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.
Liang JJ; Wang H; Rashid A; Tan TH; Hwang RF; Hamilton SR; Abbruzzese JL; Evans DB; Wang H
Clin Cancer Res; 2008 Nov; 14(21):7043-9. PubMed ID: 18981001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
